Deleobuvir
Deleobuvir[edit | edit source]
Deleobuvir is an investigational antiviral drug that was developed for the treatment of hepatitis C virus (HCV) infection. It is a non-nucleoside inhibitor of the HCV RNA polymerase, specifically targeting the NS5B protein, which is essential for viral replication.
Mechanism of Action[edit | edit source]
Deleobuvir functions by binding to the NS5B RNA-dependent RNA polymerase of the hepatitis C virus. This binding inhibits the polymerase activity, thereby preventing the replication of the viral RNA. Unlike nucleoside inhibitors, which mimic the natural substrates of the polymerase, non-nucleoside inhibitors like Deleobuvir bind to an allosteric site, inducing conformational changes that reduce the enzyme's activity.
Clinical Development[edit | edit source]
Deleobuvir was evaluated in several clinical trials to assess its efficacy and safety in combination with other antiviral agents. It was primarily tested in combination with pegylated interferon and ribavirin, as well as with other direct-acting antivirals. The goal was to achieve a sustained virologic response (SVR), which is indicative of a successful treatment outcome.
Pharmacokinetics[edit | edit source]
The pharmacokinetic profile of Deleobuvir includes its absorption, distribution, metabolism, and excretion. It is administered orally and undergoes hepatic metabolism. The drug's half-life and bioavailability are important factors in determining the dosing regimen.
Side Effects[edit | edit source]
Common side effects observed in clinical trials of Deleobuvir include fatigue, nausea, and headache. As with many antiviral therapies, the combination regimens can lead to more complex side effect profiles, necessitating careful monitoring of patients.
Discontinuation[edit | edit source]
Despite initial promise, the development of Deleobuvir was eventually discontinued. This decision was influenced by the emergence of more effective and better-tolerated antiviral agents for HCV, such as sofosbuvir and ledipasvir, which offered higher cure rates and shorter treatment durations.
Related Pages[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
